Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with short ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...

A secretive California startup just fired a machine so powerful it outpaces the energy draw of four megacities—at once. Built ...